Understanding LAG-3 Signaling
- PMID: 34067904
- PMCID: PMC8156499
- DOI: 10.3390/ijms22105282
Understanding LAG-3 Signaling
Abstract
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ago as an inhibitory immune checkpoint molecule comparable to PD-1 and CTLA-4 and a potential target for enhancing anti-cancer immune responses. LAG-3 is the third inhibitory receptor to be exploited in human anti-cancer immunotherapies, and it is considered a potential next-generation cancer immunotherapy target in human therapy, right next to PD-1 and CTLA-4. Unlike PD-1 and CTLA-4, the exact mechanisms of action of LAG-3 and its relationship with other immune checkpoint molecules remain poorly understood. This is partly caused by the presence of non-conventional signaling motifs in its intracellular domain that are different from other conventional immunoregulatory signaling motifs but with similar inhibitory activities. Here we summarize the current understanding of LAG-3 signaling and its role in LAG-3 functions, from its mechanisms of action to clinical applications.
Keywords: LAG-3; cancer signaling; immune checkpoint; immunotherapy; targeted therapy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.Immunity. 2016 May 17;44(5):989-1004. doi: 10.1016/j.immuni.2016.05.001. Immunity. 2016. PMID: 27192565 Free PMC article. Review.
-
Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.J Biol Chem. 2019 Apr 12;294(15):6017-6026. doi: 10.1074/jbc.RA119.007455. Epub 2019 Feb 13. J Biol Chem. 2019. PMID: 30760527 Free PMC article.
-
LAG-3-An incompletely understood target in cancer therapy.FASEB J. 2024 Nov 30;38(22):e70190. doi: 10.1096/fj.202401639R. FASEB J. 2024. PMID: 39560030 Free PMC article. Review.
-
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518. Immunol Rev. 2017. PMID: 28258695 Review.
-
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.EMBO Mol Med. 2024 Aug;16(8):1791-1816. doi: 10.1038/s44321-024-00098-y. Epub 2024 Jul 19. EMBO Mol Med. 2024. PMID: 39030301 Free PMC article.
Cited by
-
Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma.Front Cell Dev Biol. 2022 Nov 24;10:965803. doi: 10.3389/fcell.2022.965803. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36506094 Free PMC article. Review.
-
Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis.Diagnostics (Basel). 2021 Dec 16;11(12):2370. doi: 10.3390/diagnostics11122370. Diagnostics (Basel). 2021. PMID: 34943606 Free PMC article. Review.
-
Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies.Front Immunol. 2024 Apr 26;15:1386993. doi: 10.3389/fimmu.2024.1386993. eCollection 2024. Front Immunol. 2024. PMID: 38736877 Free PMC article. Review.
-
Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma.BMC Cancer. 2023 May 1;23(1):388. doi: 10.1186/s12885-023-10847-w. BMC Cancer. 2023. PMID: 37127623 Free PMC article.
-
Updates in Immunotherapy for Pancreatic Cancer.J Clin Med. 2024 Oct 26;13(21):6419. doi: 10.3390/jcm13216419. J Clin Med. 2024. PMID: 39518557 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
- PROYE16001ESCO/Fundación Científica Asociación Española Contra el Cáncer
- FIS PI17/02119/Instituto de Salud Carlos III
- FIS PI20/00010/Instituto de Salud Carlos III
- BMED 050-2019/Departamento de Salud, Gobierno de Navarra
- AGATA, Ref 0011-1411-2020-000013/Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra
- LINTERNA, Ref. 0011-1411-2020-000033/Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra
- DESCARTHES, 0011-1411-2019-000058/Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra
- ISOLDA; ID: 848166/Horizon 2020 Framework Programme
- TRANSPOCART ICI19/00069/Instituto de Salud Carlos III
- COV20/00000/Instituto de Salud Carlos III
LinkOut - more resources
Full Text Sources
Other Literature Sources